Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.

ABSTRACT:

Background

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has improved survival and central nervous system (CNS) outcomes in patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations. However, little is known about the efficacy and safety of combining osimertinib with chemotherapy.

Methods

This was a retrospective study performed at 3 institutions. Patients with advanced EGFR-mutated NSCLC who received concurrent osimertinib with chemotherapy in the third-line or beyond were identified by chart review. Efficacy outcomes including duration on treatment (DOT), overall survival (OS), and CNS outcomes were assessed. Safety outcomes were also evaluated.

Results

A total of 44 patients met inclusion criteria. Median DOT with osime

SUBMITTER: White MN 

PROVIDER: S-EPMC8205932 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature